After President-elect Donald Trump chose Robert Kennedy Jr., a longtime vaccine skeptic with no medical or public health training, was chosen to be the next health secretary, Eli Lilly (LLY) chair and CEO David Ricks said his company would fight to defend preserving the Food and Drug Administration as it stands today, Aimee Ortiz of The New York Times reports. Ricks said, “We’re the only country on Earth that does primary data review… I think that’s a value to society we need to keep. We’ll argue that strongly with our new regulator.”
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Viking’s VK2735 likely ‘even better’ than Lilly’s Zepbound, says BTIG
- Eli Lilly’s (LLY) Zepbound Outperformed Novo Nordisk’s Wegovy in Study
- Salesforce up after Q3, GM outlines $5B in China business charges: Morning Buzz
- Morning Movers: Salesforce jumps after Q3, Foot Locker sinks after guidance cut
- Eli Lilly announces topline results from SURMOUNT-5 trial